Showing 81 - 100 results of 115 for search 'USA Boxing', query time: 0.05s Refine Results
  1. 81
  2. 82
  3. 83
  4. 84
  5. 85
  6. 86

    Exploring the optimal reconstruction strategy for Enneking III defects in pelvis bone tumors: a finite element analysis by Jiazhuang Zhu, Jianping Hu, Kunpeng Zhu, Xiaolong Ma, Zhen Huang, Chunlin Zhang

    Published 2025-01-01
    “…We subsequently conducted simulations of static FEA under natural walking loads using ANSYS software (version 2022R1, Canonsburg, Pennsylvania, USA). Results Compared with Scheme A, reconstruction of the Enneking III region (Schemes B and C) led to a more uniform stress distribution and lower peak stress in the pelvis. …”
    Get full text
    Article
  7. 87
  8. 88
  9. 89

    Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017 by Bao Liu, Xingyue Zhu

    Published 2022-07-01
    “…Objective To explore the associations between the risks of postmarketing safety events of new drugs and the four expedited programmes of priority review, accelerated approval, fast track and breakthrough therapy established by the US Food and Drug Administration (FDA); and to investigate whether multiple uses of expedited programmes, and the combinations of expedited programmes with orphan designation, were relevant to different safety profiles.Design Cohort study.Setting USA.Participants All new drugs approved by the FDA between 1 January 2007 and 31 December 2017, followed up until 10 April 2021.Outcome measures Safety events included safety-related withdrawal, new boxed warning, drug safety communication, postapproval risk evaluation mitigation strategy and safety-related labelling changes. …”
    Get full text
    Article
  10. 90
  11. 91
  12. 92
  13. 93
  14. 94
  15. 95
  16. 96

    Brodalumab: Six-Year US Pharmacovigilance Report by Mark G. Lebwohl, John Y. Koo, April W. Armstrong, Bruce E. Strober, Soo Han Yoon, Nicole N. Rawnsley, Earl L. Goehring, Gina D. Mangin, Abby A. Jacobson

    Published 2024-11-01
    “…Abstract Introduction Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the USA, brodalumab has a boxed warning regarding suicidal ideation and behavior and is only available under a Risk Evaluation and Mitigation Strategy, but no causal association has been established. …”
    Get full text
    Article
  17. 97
  18. 98
  19. 99
  20. 100